-->

Tag: PD-1 inhibitor combinations

Home / PD-1 inhibitor combinations

Categories

Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma

March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment...
pd-1-inhibitor-combinations

Pembrolizumab with chemotherapy is approved by the USFDA for biliary tract cancer

On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin to treat biliary tract carcinoma (BTC) that has spread or is l...
pd-1-inhibitor-combinations

Scan the code